Jarrod Longcor
Cellectar Biosciences · Chief Operating Officer
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jarrod Longcor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:31 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07311993 · Phase 1 Study of CLR 125 in Triple Negative Breast CancerCellectar Biosciences, Inc. · recruiting · Breast Cancer · study director
- Ph1NCT05610891 · Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGCellectar Biosciences, Inc. · active not recruiting · High-Grade Glioma · study director
- Ph1NCT03478462 · Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasCellectar Biosciences, Inc. · active not recruiting · Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor · study director
- Ph2NCT02952508 · Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromCellectar Biosciences, Inc. · active not recruiting · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade GliomaR44CA272070 · NCI · CELLECTAR BIOSCIENCES, INC. · fiscal years 2022 to 2023 · $965,201 awarded in 2023Same name and institution; not confirmed by an ID
- An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms MacroglobulinemiaR44CA265558 · NCI · CELLECTAR BIOSCIENCES, INC. · fiscal years 2021 to 2023 · $475,806 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in atypical teratoid rhabdoid tumour (at/rt).